Abstract
Over the past 10 years, leukemias and lymphomas have been analyzed extensively with antibodies and for enzyme activity [1, 2]. More recently, the introduction of monoclonal antibodies (MoAbs) has improved dramatically the precision, practicability, and standardization of immunophenotyping. Meanwhile, immunologic analysis of leukemia cells has become routine clinical practice, and evidence that cell typing with antibodies contributes to final diagnosis, differential diagnosis, and classification of leukemias is compelling [3].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
